Literature DB >> 19292873

Functional and structural characterization of novel mutations and genotype-phenotype correlation in 51 phenylalanine hydroxylase deficient families from Southern Italy.

Aurora Daniele1, Iris Scala, Giuseppe Cardillo, Cinzia Pennino, Carla Ungaro, Michelina Sibilio, Giancarlo Parenti, Luciana Esposito, Adriana Zagari, Generoso Andria, Francesco Salvatore.   

Abstract

Hyperphenylalaninemia (Online Mendelian Inheritance in Man database: 261600) is an autosomal recessive disorder mainly due to mutations in the gene for phenylalanine hydroxylase; the most severe form of hyperphenylalaninemia is classic phenylketonuria. We sequenced the entire gene for phenylalanine hydroxylase in 51 unrelated hyperphenylalaninemia patients from Southern Italy. The entire locus was genotyped in 46 out of 51 hyperphenylalaninemia patients, and 32 different disease-causing mutations were identified. The pathologic nature of two novel gene variants, namely, c.707-2delA and p.Q301P, was demonstrated by in vitro studies. c.707-2delA is a splicing mutation that involves the accepting site of exon 7; it causes the complete skipping of exon 7 and results in the truncated p.T236MfsX60 protein. The second gene variant, p.Q301P, has very low residual enzymatic activity (approximately 4.4%), which may be ascribed, in part, to a low expression level (8-10%). Both the decreased enzyme activity and the low expression level are supported by analysis of the 3D structure of the molecule. The putative structural alterations induced by p.Q301P are compatible with protein instability and perturbance of monomer interactions within dimers and tetramers, although they do not affect the catalytic site. In vivo studies showed tetrahydrobiopterin responsiveness in the p.Q301P carrier but not in the c.707-2delA carrier. We next investigated genotype-phenotype correlations and found that genotype was a good predictor of phenotype in 76% of patients. However, genotype-phenotype discordance occurred in approximately 25% of our patients, mainly those bearing mutations p.L48S, p.R158Q, p.R261Q and p.P281L.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19292873     DOI: 10.1111/j.1742-4658.2009.06940.x

Source DB:  PubMed          Journal:  FEBS J        ISSN: 1742-464X            Impact factor:   5.542


  12 in total

1.  Long-term pharmacological management of phenylketonuria, including patients below the age of 4 years.

Authors:  M L Couce; M D Bóveda; E Valerio; A Pérez-Muñuzuri; J M Fraga
Journal:  JIMD Rep       Date:  2011-09-06

2.  Further defining the clinical and molecular spectrum of acromesomelic dysplasia type maroteaux: a Turkish tertiary center experience.

Authors:  Pelin Ozlem Simsek-Kiper; Gizem Urel-Demir; Ekim Z Taskiran; Umut Ece Arslan; Banu Nur; Ercan Mihci; Mithat Haliloglu; Yasemin Alanay; Gulen Eda Utine; Koray Boduroglu
Journal:  J Hum Genet       Date:  2020-12-07       Impact factor: 3.172

3.  Identification of mutations underlying 20 inborn errors of metabolism in the United Arab Emirates population.

Authors:  Imen Ben-Rebeh; Jozef L Hertecant; Fatma A Al-Jasmi; Hanan E Aburawi; Said A Al-Yahyaee; Lihadh Al-Gazali; Bassam R Ali
Journal:  Genet Test Mol Biomarkers       Date:  2011-11-22

Review 4.  New protein structures provide an updated understanding of phenylketonuria.

Authors:  Eileen K Jaffe
Journal:  Mol Genet Metab       Date:  2017-06-15       Impact factor: 4.797

5.  The Missense p.S231F phenylalanine hydroxylase gene mutation causes complete loss of enzymatic activity in vitro.

Authors:  Maja Stojiljkovic; Belén Pérez; Lourdes R Desviat; Cristina Aguado; Magdalena Ugarte; Sonja Pavlovic
Journal:  Protein J       Date:  2009-08       Impact factor: 2.371

6.  Phenylketonuria in Portugal: Genotype-phenotype correlations using molecular, biochemical, and haplotypic analyses.

Authors:  Filipa Ferreira; Luísa Azevedo; Raquel Neiva; Carmen Sousa; Helena Fonseca; Ana Marcão; Hugo Rocha; Célia Carmona; Sónia Ramos; Anabela Bandeira; Esmeralda Martins; Teresa Campos; Esmeralda Rodrigues; Paula Garcia; Luísa Diogo; Ana Cristina Ferreira; Silvia Sequeira; Francisco Silva; Luísa Rodrigues; Ana Gaspar; Patrícia Janeiro; António Amorim; Laura Vilarinho
Journal:  Mol Genet Genomic Med       Date:  2021-01-19       Impact factor: 2.183

7.  Long-term follow-up of patients with phenylketonuria treated with tetrahydrobiopterin: a seven years experience.

Authors:  Iris Scala; Daniela Concolino; Roberto Della Casa; Anna Nastasi; Carla Ungaro; Serena Paladino; Brunella Capaldo; Margherita Ruoppolo; Aurora Daniele; Giuseppe Bonapace; Pietro Strisciuglio; Giancarlo Parenti; Generoso Andria
Journal:  Orphanet J Rare Dis       Date:  2015-02-08       Impact factor: 4.123

8.  Structural features of the regulatory ACT domain of phenylalanine hydroxylase.

Authors:  Carla Carluccio; Franca Fraternali; Francesco Salvatore; Arianna Fornili; Adriana Zagari
Journal:  PLoS One       Date:  2013-11-14       Impact factor: 3.240

9.  Altered brain protein expression profiles are associated with molecular neurological dysfunction in the PKU mouse model.

Authors:  Esther Imperlini; Stefania Orrù; Claudia Corbo; Aurora Daniele; Francesco Salvatore
Journal:  J Neurochem       Date:  2014-03-24       Impact factor: 5.372

10.  Genotype-phenotype associations in French patients with phenylketonuria and importance of genotype for full assessment of tetrahydrobiopterin responsiveness.

Authors:  Elise Jeannesson-Thivisol; François Feillet; Céline Chéry; Pascal Perrin; Shyue-Fang Battaglia-Hsu; Bernard Herbeth; Aline Cano; Magalie Barth; Alain Fouilhoux; Karine Mention; François Labarthe; Jean-Baptiste Arnoux; François Maillot; Catherine Lenaerts; Cécile Dumesnil; Kathy Wagner; Daniel Terral; Pierre Broué; Loïc de Parscau; Claire Gay; Alice Kuster; Antoine Bédu; Gérard Besson; Delphine Lamireau; Sylvie Odent; Alice Masurel; Jean-Louis Guéant; Fares Namour
Journal:  Orphanet J Rare Dis       Date:  2015-12-15       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.